Therefore, early memory CD8+ T cells and CAR-TSCM play crucial roles in achieving long-term clinical remission in patients with hematologic malignancies by maintaining self-renewal capacity, ensuring optimal functionality, and providing durable antitumor immune responses (37). This evidence concerns the gene CD8A and hematologic disorder.